CCO Annual Update
Hepatitis Annual Update 2008
Can Hepatitis B Be Cured? |
Module 1 of 9 |
|
Co-Chair: Norah Terrault, MD, MPH
|
|
Marc G. Ghany, MD, discusses cccDNA and its role in the difficult path of obtaining a true cure for HBV infection
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize the mechanisms of HBV cccDNA creation, maintenance, and elimination
- Describe the impact of current antiviral therapies on the rate of HBsAg seroconversion and HBV cccDNA suppression
- Discuss the impact of current antiviral therapies on the rate of disease progression and the development of hepatocellular carcinoma
- Relate how and when reactivation from anti-HBs and anti-HBc positivity to HBsAg positivity occurs
Abstract
|
Therapy of Chronic Hepatitis B: Who to Treat and When to Treat? A Case-Based Discussion |
Module 2 of 9 |
|
Co-Chair: Norah Terrault, MD, MPH
|
|
Anna S. F. Lok, MD, discusses factors to consider when screening patients with chronic hepatitis B infection for treatment initiation.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe management strategies for the treatment of chronic hepatitis B in various case scenarios
- Identify characteristics used to determine when treatment should be delayed or initiated in patients with chronic hepatitis B
- Discuss treatment guidelines for chronic hepatitis B
|
Therapy of Chronic Hepatitis B: What to Choose, When to Change, and When to Stop |
Module 3 of 9 |
|
Co-Chair: Norah Terrault, MD, MPH
|
|
Join Ira M. Jacobson, MD, as he reviews the latest data on which HBV therapy to choose, when to change, and when to stop.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the available treatment options when initiating hepatitis B virus therapy
- Recount the factors involved in determining when to continue vs change current therapy
- List the endpoints of therapy used to determine when treatment should be discontinued
- Discuss new treatment data and the advantages and disadvantages of current treatment options
|
New Data on Currently Available HCV Therapies and Their Impact on Initial Treatment Strategies |
Module 4 of 9 |
|
Co-Chair: Raymond T. Chung, MD
|
|
Mark S. Sulkowski, MD, reviews principles and strategies for hepatitis C treatment using currently available therapeutic agents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the use of viral kinetic principles to determine duration of initial therapy
- Summarize initial treatment of hepatitis C for special, difficult-to-treat populations
- Describe strategies for tailoring and individualizing initial therapy in hepatitis C
|
Strategies for Management of Hepatitis C Treatment Failure |
Module 5 of 9 |
|
Co-Chair: Mark S. Sulkowski, MD
- Karen L. Lindsay, MD, MMM
|
|
|
Karen L. Lindsay, MD, MMM, reviews the latest data on the management of patients who were nonresponders or relapsers during HCV therapy.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss strategies for altering the use of interferon in the management of nonresponders or relapsers, including the use of high-dose interferon and alternative interferon formulations
- Review recent trial data regarding the role of maintenance therapy in nonresponders or relapsers to hepatitis C virus treatment
- Describe when to recommend deferral of retreatment of hepatitis C nonresponders or relapsers
Abstract
|
HCV Therapy: What Will the Future Look Like? |
Module 6 of 9 |
|
Co-Chair: Mark S. Sulkowski, MD
|
|
David R. Nelson, MD, reviews investigational agents and emerging treatment strategies for hepatitis C.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe hepatitis C virology relevant to investigational agents for hepatitis C
- Discuss new treatment efficacy data for investigational, targeted therapies for hepatitis C
- Recall resistance data for investigational hepatitis C agents
- Discuss data regarding the role of peginterferon and ribavirin in future hepatitis C treatment algorithms
Abstract
|
Update on Autoimmune Hepatitis: Management Strategies |
Module 7 of 9 |
|
Co-Chair: Raymond T. Chung, MD
|
|
Join Michael P. Manns, MD, as he presents updates on the identification and clinical management of autoimmune hepatitis.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize the diagnostic criteria for autoimmune hepatitis with a focus on understanding the nonspecificity of a positive antinuclear antibody test in a patient with liver disease
- Discuss current treatment and maintenance algorithms for patients with autoimmune hepatitis, including alternative agents for patients who respond poorly to prednisone and azathioprine
- Describe how the cholestatic autoimmune diseases differ from autoimmune hepatitis in presentation, course, and therapy
|
Managing the Complications of Cirrhosis |
Module 8 of 9 |
|
Co-Chair: Raymond T. Chung, MD
- Guadalupe Garcia-Tsao, MD
|
|
|
Guadalupe Garcia-Tsao, MD, reviews strategies for managing the clinical complications of cirrhosis.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the incidence and types of clinical complications of cirrhosis
- Summarize updates on current standards of care regarding management of cirrhosis complications, particularly refractory ascites, bacterial peritonitis, hyponatremia, encephalopathy, variceal bleeding, and hepatorenal syndrome
- Outline a strategy for surveillance for hepatocellular carcinoma in cirrhotic patients and options for management of tumors
- Discuss indications for referral for liver transplantation
|
Hepatitis Journal Club: Top Clinical Articles of 2007-08 |
Module 9 of 9 |
|
Co-Chair: Raymond T. Chung, MD
|
|
Jorge L. Herrera, MD, reviews the top hepatology articles from the past year and reviews their applications for clinical practice.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recount the top 5-10 clinical findings in liver disease between February 2007 and February 2008
- Discuss how the top findings in liver disease over the past year have advanced the field
- Describe what changes in clinical practice will come about from the top advances in liver disease over the past year
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|